Publications
101
Citations
1,329
Est. group size
~1
Recurring co-author estimate
Active years
23
Publishing since 2004
Anita Turk conducts clinical cancer research focused on gastrointestinal cancers, including colorectal, pancreatic, and biliary tract (liver and bile duct) cancers. Much of the work involves clinical trials testing new drug combinations, immunotherapies, and targeted treatments, as well as studies of tumor biology and biomarkers that predict treatment response. The research spans early-phase drug trials, treatment guidelines, and studies of how tumors interact with the immune system.
Publication activity has grown over the last decade, rising from a handful of papers per year in the late 2010s to a peak around 2022 and remaining consistently active since.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Data from Tumor Matrix Proteoglycan Accumulation and Processing Alter T-cell Effector Function and the Response to Immunotherapy in Patients with Oligometastatic Colorectal Cancer
2026
- Supplementary Figures S1-S14 from Tumor Matrix Proteoglycan Accumulation and Processing Alter T-cell Effector Function and the Response to Immunotherapy in Patients with Oligometastatic Colorectal Cancer
2026
- Clinical Trial Protocol from Tumor Matrix Proteoglycan Accumulation and Processing Alter T-cell Effector Function and the Response to Immunotherapy in Patients with Oligometastatic Colorectal Cancer
2026
- Supplementary Tables S1-S6 from Tumor Matrix Proteoglycan Accumulation and Processing Alter T-cell Effector Function and the Response to Immunotherapy in Patients with Oligometastatic Colorectal Cancer
2026
- Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial
The Oncologist · 2026
- Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network · 2025
- Early-Onset Colorectal Cancer: From Genetic Discovery to Clinical Innovation
American Society of Clinical Oncology Educational Book · 2025
- Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring <i>IDH1</i> or <i>IDH2</i> Mutations
Clinical Cancer Research · 2025
- Stakeholder understanding of social prescribing in England: a qualitative study in primary care
BMC Primary Care · 2025
- Phase II Study of Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and Fluorouracil in Locally Advanced Pancreatic Carcinoma: BTCRC-GI15-067
JCO oncology advances. · 2025
- Phase II Study of Ipilimumab, Nivolumab, and Panitumumab in Patients With <i>KRAS</i> / <i>NRAS</i> / <i>BRAF</i> Wild-Type Microsatellite Stable Metastatic Colorectal Cancer
JCO oncology advances. · 2025
- A phase II study of pembrolizumab, carboplatin, paclitaxel, and radiation for the treatment of early-stage anal cancer: Big Ten Cancer Research Consortium GI22-588.
Journal of Clinical Oncology · 2025
- A phase II study of pevonedistat in combination with carboplatin and paclitaxel in advanced intrahepatic cholangiocarcinoma: ECOG-ACRIN EA2187.
Journal of Clinical Oncology · 2025
- Data from Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring <i>IDH1</i> or <i>IDH2</i> Mutations
2025
- Supplementary Data 1 from Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring <i>IDH1</i> or <i>IDH2</i> Mutations
2025
- Journal of Clinical Oncology×26
- Figshare×13
- Cancer Research×6
- The Oncologist×3
- Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie×3
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile